Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-06-12

Lead Sponsor: Northwestern University

Registration Number: NCT00004907

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer

Phase 3

Completed

Conditions: Mediastinal Cancer
Metastatic Cancer
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 222

Registration Number: NCT00003941

Locations: 🇧🇪
Institut Jules Bordet, Brussels (Bruxelles), Belgium
🇩🇪
St. Johannes Hospital - Medical Klinik II, Duisburg, Germany
🇩🇪
Universitaetsklinikum Halle, Halle (Saale), Germany

and more 34 locations

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2012-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 400

Registration Number: NCT00003215

Locations: 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Combination Chemotherapy in Treating Men With Germ Cell Cancer

Phase 2

Conditions: Extragonadal Germ Cell Tumor
Teratoma
Testicular Germ Cell Tumor

First Posted Date: 2003-01-27

Last Posted Date: 2012-03-06

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 498

Registration Number: NCT00003643

Locations: 🇩🇪
Klinikum der Stadt Mannheim, Mannheim, Germany
🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇩🇰
Aarhus Universitetshospital - Aarhus Sygehus, Aarhus, Denmark

and more 66 locations